title: Cilostazol reduces periprocedural hemodynamic depression in carotid artery stenting.
abstract: The clinical effects of two different types of antiplatelet drugs, cilostazol and thienopyridine drugs, were compared in patients treated by carotid artery stenting (CAS). Two hundred patients scheduled for CAS were randomized to either cilostazol or a thienopyridine drug (ticlopidine or clopidogrel). The study was conducted in open-label design. Aspirin was also given to all patients. All episodes of periprocedural hemodynamic instability (bradycardia, hypotension) were recorded together with all instances of stroke, cardiac morbidity, and death within 30 days of the procedure. Angiographic follow-up studies were conducted about 6 months after CAS. Finally, 197 patients were enrolled in this study; 97 were treated with cilostazol (cilostazol group) and 100 with a thienopyridine drug (thienopyridine group). In the 30-day follow-up period, the incidence of stroke, cardiac adverse effects, and death was not significantly different between the 2 groups (cilostazol group 7.2%, thienopyridine group 11.0%; p = 0.85). The incidence of intra- and postprocedural bradycardia was significantly lower in the cilostazol group (cilostazol group 18.6% and 2.1%, thienopyridine group 40.0% and 18.0%, respectively; p < 0.01). Although the incidence of intraprocedural hypotension did not significantly differ between the 2 groups, postprocedural hypotension was significantly lower in the cilostazol group (16.5% vs. 34.0%, p < 0.01). In-stent restenosis on follow-up angiograms was lower in the cilostazol group but not significantly (0% vs. 4.4%, p = 0.12). This small open-label study shows that cilostazol may reduce periprocedural bradycardia and hypotension compared with thienopyridine drugs in patients treated by CAS.
authors.affiliation: Department of Neurosurgery and Neuroradiology, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan. tsutsumi@fukuoka-u.ac.jp
authors.forename: Masanori
authors.initials: M
authors.lastname: Tsutsumi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Aikawa
authors.forename: Kouhei
authors.initials: K
authors.lastname: Nii
authors.forename: Housei
authors.initials: H
authors.lastname: Etou
authors.forename: Kimiya
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Kureshima
authors.forename: Ritsurou
authors.initials: R
authors.lastname: Inoue
authors.forename: Hidenori
authors.initials: H
authors.lastname: Yoshida
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: Sumito
authors.initials: S
authors.lastname: Narita
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kazekawa
mesh_terms: D000368:Aged; D017130:Angioplasty / Q000009:adverse effects*; D001919:Bradycardia / Q000209:etiology / Q000517:prevention & control*; D016893:Carotid Stenosis / Q000601:surgery*; D000077407:Cilostazol; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D007022:Hypotension / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D015607:Stents; D013777:Tetrazoles / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine